These preclinical experiments suggest that HDAC3-specific inhibition may be an effective therapy for GCB lymphomas, particularly those with CREBBP-mutations, by reducing the dominance of BCL6 on transcription programs and improving both terminal differentiation and immunogenicity of tumor cells. This evidence concerns the gene BCL6 and neoplasm.